Real‐world data on primary cutaneous lymphoproliferative disorders following <scp>SARS‐CoV</scp>‐2 vaccination: A multicentre experience from tertiary referral hospitals

Avallone, Gianluca; Maronese, Carlo Alberto; Conforti, Claudio; Fava, Paolo; Gargiulo, Luigi; Marzano, Angelo Valerio; Massone, Cesare; Mastorino, Luca; Paradisi, Andrea; Pileri, Alessandro; Quaglino, Pietro; Rizzo, Nicola; Ribero, Simone; Roccuzzo, Gabriele; Tavoletti, Gianluca; Vignoli, Carlo Alberto; Zalaudek, Iris; Berti, Emilio; Alberti‐Violetti, Silvia

doi:10.1111/jdv.18806

Cited by 6 publications

(23 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 More recently, 14 cases of primary cutaneous LPDs related to COVID-19 vaccination, varying from MF, Sezary syndrome, LyP, cutaneous CD4 + small/medium T-cell LPD to cutaneous lymphoid hyperplasia were reported. 3 All 14 patients received the Pfizer vaccine as the first dose, while a few patients received the Moderna vaccine as their second dose. Interestingly, in this cohort, besides eight cases with new onset of LPDs, five patients relapsed and one patient progressed from their pre-existing LPDs.…”

Section: Discussionmentioning

confidence: 99%

“…8 Conversely, there were rare reports of LPDs underwent regression following COVID-19 vaccination. 9 Although the Pfizer vaccine seemed to be more frequently implicated in some series, 2,3 LPDs following Moderna, AstraZeneca, or other F I G U R E 1 A firm, erythematous nodule over the left upper arm at the site of vaccine inoculation and a smaller papule located laterally to the nodule (consent was obtained for the photograph). vector vaccines have also been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Three clinicopathologic presentations were identified among these patients, including LyP, PLEVA, and cutaneous T‐cell lymphoid hyperplasia 2 . More recently, 14 cases of primary cutaneous LPDs related to COVID‐19 vaccination, varying from MF, Sezary syndrome, LyP, cutaneous CD4 + small/medium T‐cell LPD to cutaneous lymphoid hyperplasia were reported 3 . All 14 patients received the Pfizer vaccine as the first dose, while a few patients received the Moderna vaccine as their second dose.…”

Section: Discussionmentioning

confidence: 99%

“…1 In addition, a number of cutaneous lymphoid reactions (CLRs), including mycosis fungoides (MF), lymphomatoid papulosis (LyP), pityriasis lichenoides et varioliformis acuta (PLEVA), primary cutaneous CD4 + small/ medium T-cell lymphoproliferative disorder (LPD), and cutaneous T-cell lymphoid hyperplasia, have been reported after COVID-19 vaccination. 2,3 Of the patients who developed CLRs, some were new onsets of CLRs while others were relapses or worsening of the preexisting disease after remission. The vast majority of the reported CLRs after COVID-19 vaccine are T-cell LPDs, except one case of extranodal/nodal marginal zone lymphoma (MZL).…”

Section: Introductionmentioning

confidence: 99%

“…The most common are injection site reactions, urticaria, morbilliform eruptions, and delayed hypersensitivity reactions 1 . In addition, a number of cutaneous lymphoid reactions (CLRs), including mycosis fungoides (MF), lymphomatoid papulosis (LyP), pityriasis lichenoides et varioliformis acuta (PLEVA), primary cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder (LPD), and cutaneous T‐cell lymphoid hyperplasia, have been reported after COVID‐19 vaccination 2,3 . Of the patients who developed CLRs, some were new onsets of CLRs while others were relapses or worsening of the pre‐existing disease after remission.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Primary cutaneous marginal zone lymphoproliferative disorder following COVID‐19 vaccination

Stephan,

Barone,

Kim

et al. 2023

J Cutan Pathol

View full text Add to dashboard Cite

During the coronavirus disease 2019 (COVID‐19) pandemic, COVID‐19 vaccines were administered worldwide. A number of skin reactions, including primary cutaneous T‐cell lymphoproliferative disorders (LPDs) were reported following COVID‐19 vaccination. We report a case of primary cutaneous marginal zone lymphoproliferative disorder (PCMZLPD) secondary to COVID‐19 vaccination. A 57‐year‐old man presented with an erythematous nodule on his left arm at the site of vaccine inoculation following his first dose of the Moderna (mRNA‐1273) vaccine a few weeks prior. The nodule continued to progress in size after the second dose. A skin biopsy specimen of the nodule showed a diffuse dermal infiltrate of small to medium‐sized lymphocytes with plasma cells and histiocytes. The infiltrate was composed of CD3+ T cells with CD20+ and CD79a+ B cells. The neoplastic B cells reacted with BCL‐2 and were negative for BCL‐6 and CD10. Kappa light chain restriction was identified by in situ hybridization. Gene rearrangement studies revealed kappa light chain monoclonality, confirming the diagnosis of PCMZLPD. The temporal association with the Moderna vaccination and the occurrence of the lesion at the inoculation site indicate a COVID‐19 vaccination‐induced PCMZLPD. This is one of the rare cases of PCMZLPD following COVID‐19 vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%